During the developing COVID-19 pandemic, the Nuffield Department of Medicine Research Building is taking measures to prevent the spread of the disease.
Departments are instructed by the University's Registrar to continue to work from home where possible, and manage the return to on site working, based on the University guidelines for risk assessments and work prioritisation.
This is to restrict contact between individuals as far as possible. The University remains open and operating as far as possible with the following restrictions:
- No public access to the University
-
On-site activity permitted where it cannot be undertaken remotely, driven by safety, capacity and other factors such as schools reopening/other changes in government guidelines
-
Teaching and assessment are undertaken remotely where possible and, depending on government guidelines, gatherings of staff and students only permitted where essential for teaching and assessment to take place
Podcast: Meet our researchers
LATEST NEWS
Oxford University vaccine developer joins day of vaccinations at the Kassam Stadium
27 January 2021
Today, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.
PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19
26 January 2021
In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.
Events
Recent publications
-
The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification
Journal article
Wells CI. et al, (2021), International Journal of Molecular Sciences, 22, 566 - 566
-
The deubiquitinase TRABID stabilises the K29/K48-specific E3 ubiquitin ligase HECTD1.
Journal article
Harris LD. et al, (2021), The Journal of biological chemistry
-
The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers.
Journal article
Lumley SF. et al, (2021), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
-
Chapter 7: Public-Private Partnerships to Advance Phenotypic Drug Discovery
Chapter
Carragher N. et al, (2021), RSC Drug Discovery Series, 2021-January, 118 - 139
-
The deubiquitinase TRABID stabilises the K29/K48-specific E3 ubiquitin ligase HECTD1
Journal article
Harris LD. et al, (2020), Journal of Biological Chemistry, jbc.RA120.015162 - jbc.RA120.015162
-
Inflammatory Endotype Associated Airway Microbiome in COPD Clinical Stability and Exacerbations – A Multi-Cohort Longitudinal Analysis
Journal article
Wang Z. et al, (2020), American Journal of Respiratory and Critical Care Medicine